Functional interactions between polypyrimidine tract binding protein and PRI peptide ligand containing proteins. by Coelho, MB et al.
  
1 
Functional interactions between Polypyrimidine Tract Binding Protein 
and PRI peptide ligand containing proteins 
 
1Miguel B. Coelho, 1David B. Ascher, 1Clare Gooding, 1Emma Lang, 1Hannah 
Maude, 1David Turner, 1Miriam Llorian, 1,3Douglas E.V. Pires, 2Jan Attig & 
1Christopher WJ Smith 
 
1Department of Biochemistry, University of Cambridge, Tennis Court Road, 
Cambridge CB2 1QW 
2Department of Molecular Neuroscience, UCL Institute of Neurology, Queen 
Square, London, WC1N 3BG, UK 
3Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Avenida 
Augusto de Lima 1715, Belo Horizonte, 30190-002, Brazil 
 
 
 
 
 
Tel: 01223-333655 
Fax: 01223-766002 
Email: cwjs1@cam.ac.uk 
 
 
Keywords: alternative_splicing, Polypyrimidine_tract_binding_protein, PTB, 
Matrin3, hnRNP, RNA 
 
  
2 
Abstract 
Polypyrimidine Tract Binding protein (PTBP1) is a heterogeneous nuclear 
ribonucleoprotein (hnRNP) that plays roles in most stages of the life-cycle of 
pre-mRNA and mRNAs in the nucleus and cytoplasm. PTBP1 has four RNA 
binding domains of the RNA Recognition Motif (RRM) family, each of which 
can bind to pyrimidine motifs. In addition, RRM2 can interact via its dorsal 
surface with proteins containing short peptide ligands known as PTB RRM2 
Interacting (PRI) motifs, originally found in the protein Raver1. Here we review 
our recent progress in understanding the interactions of PTB with RNA and 
with various proteins containing PRI ligands. 
 
Introduction 
PTBP1 acts widely as a regulator of alternative splicing, primarily as a 
repressor but also as an activator depending upon where it binds relative to a 
regulated exon [1, 2]. It also regulates use of some 3´ end 
processing/polyadenylation sites, internal ribosome entry site (IRES) driven 
translation, cytoplasmic localization and mRNA stability (reviewed in [3]), 
including by influencing Nonsense Mediated mRNA Decay (NMD) [4]. 
Strikingly, knockdown of PTBP1 promotes conversion of fibroblasts to neuron-
like cells, principally by affecting a network of miRNA-regulated mRNAs [5]. In 
addition to PTBP1, mammals possess two paralogs — PTBP2 (also known as 
nPTB or brPTB) and PTBP3 (also known as ROD1), both of which are 
regulated post-transcriptionally by PTBP1 (Fig. 1). Skipping of PTBP2 exon 
10 is promoted by PTBP1, leading to frameshifting and NMD, thereby 
restricting PTBP2 expression to cells where PTBP1 levels are reduced 
(reviewed in [6-8]). PTBP1 and PTBP2 also promote exon 2 skipping in 
PTBP3, leading to production of N-terminally truncated protein isoforms 
initiating at internal AUG codons 4 and 11. Both these isoforms show a higher 
degree of cytoplasmic localization, due to loss of the bipartite nuclear 
localization signal, and the shorter AUG11 isoform also has a truncated 
RRM1 domain [9, 10](Fig.1). While the switch from PTBP1 to PTBP2 
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expression is known to play an important role in neuronal differentiation [8, 11, 
12], the key physiological roles of PTBP3 and of the PTBP1/2 regulation of 
PTBP3 isoforms are not yet known, although from its expression patterns 
PTBP3 is thought to have roles in hematopoietic cells.  
There are many open questions about the molecular and physiological 
functions of the PTBP proteins. These include the extent to which the PTBP1, 
2 and 3 paralogs and their isoforms have unique non-redundant activities 
which are important in various developmental settings. While much progress 
has been made in understanding the PTBP1/2 axis in neuronal biology 
(reviewed in [8]), very little is known about PTBP3, which may play equally 
important roles in hematopoietic cells. Another key set of questions concern 
the molecular basis of PTBP1 regulation of various post-transcriptional 
processes. Although interaction with target pre-mRNAs/mRNAs may in some 
cases be sufficient for activity, by specifically blocking access of other factors, 
in other cases PTBP1 also interacts with other proteins or snRNAs to effect its 
function. Here we focus on PTBP1 activity as a splicing regulator.  
 
RNA binding by PTB proteins 
The PTBP proteins possess four RRM domains, with an N-terminal extension 
containing nuclear localization and nuclear export sequence motifs, flexible 
linkers between RRMs 1, 2 and 3 (Fig. 2A), and a linker between RRMs 3 and 
4 that contributes to back-to-back packing of the two domains [13]. All four 
RRMs are able to bind RNA, with recognition of a core CU motif by RRMs 1, 2 
and 3 [13, 14]. Crosslinking immunoprecipitation (CLIP) studies have shown 
widespread binding of PTBP1 to RNA, particularly in introns [2, 15], and 
integration with transcriptome-wide data for PTBP1 knockdown has shown 
how the position of binding on the pre-mRNA relates to its activity as a 
repressor or activator. PTBP1 binding upstream of and within regulated exons 
leads to repression, while binding downstream of the exon is associated with 
activation of splicing [1, 15].  
Complementing the transcriptome-wide analyses we carried out a 
detailed analysis of how the individual RRMs of PTBP1 dock onto a well 
characterized target RNA: the PTBP1 repressed exon 6 of human FAS pre-
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mRNA [16]. We used a combination of mutations designed to impair RNA 
binding by individual RRMs [17], along with a panel of mutants each of which 
has a single cysteine residue strategically located adjacent to the RNA 
binding surface of one of the RRMs, allowing mapping of the contact sites by 
tethered hydroxyl radical probing [18]. We found a distinctly uneven division of 
labour, with the C-terminal RRMs 3 and 4 contributing more to regulation of 
FAS exon 6 than RRMs 1 and 2 [19]. Surprisingly, RRM4, which has the 
lowest intrinsic specificity recognising only a YC dinucleotide [13], is the most 
important RRM for PTBP1 function, consistent with an earlier report [20]. 
Mutation of YC contact points on the RNA prevented RRM4 binding at that 
site but did not impair function, presumably due to the ready availability of 
alternative nearby YC sites. In contrast, mutations of RRM4 that impair RNA 
binding affect splicing repressor activity more severely than mutation of any 
other RRM [19]. RNA binding by RRM3, di-domain packing of RRMs 3 and 4, 
and formation of a surface electropositive patch upon didomain packing [21], 
which extends the binding surface for RNA bound at RRM4, were also found 
to be important for function [19]. RRMs 1 and 2 showed fewer and weaker 
binding contacts with FAS pre-mRNA. Sharma and colleagues have found 
that RRMs 1 and 2 contact stem-loop IV of U1 snRNA bound at the 5´ splice 
site of the CSRC N1 exon [22]. If this is a general mechanism of repression it 
could explain the lower level of contact of these RRMs with FAS pre-mRNA.  
 
Protein binding by PTBP1 
While much attention has understandably focused upon its interactions with 
RNA, PTBP1 is also involved in a number of protein-protein interactions (for 
systematic analyses, see [23, 24]). Some of the reported interactions might be 
RNA-mediated, possibly reflecting indirect interactions bridged by common 
RNA targets. Co-association on the same RNA by PTBP1 and other proteins 
could be functionally important even in the absence of direct protein-protein 
interactions. For example a cytoplasmic RNA-bound complex of PTBP1 with 
YBX1, PSF and NONO/p54 promotes IRES driven translation of a subset of 
mRNAs in response to apoptotic stimuli [25]. Moreover, we found that PTBP1 
interacts directly with muscleblind like protein 1 (MBNL1) in an RNA-
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dependent manner, requiring RNA binding only by MBNL1, suggesting that 
RNA binding induces a conformational change in MBNL1 to promote 
interaction with PTBP1, which could be important in a subset of co-regulated 
alternative splicing events (ASEs) [26]. For the majority of reported PTBP1-
protein interactions the details of the interaction remain sketchy. An exception 
is the interaction of RRM2 with short peptide ligands.  
Peptide mediated interactions with PTBP1 RRM2 
Our focus upon RRM2 arose from structure-function analysis using an 
artificial MS2 tethering assay [27]. A PTBP1 binding site downstream of Tpm1 
exon 3 was replaced by a bacteriophage MS2 coat protein binding site, 
leading to loss of PTBP1 mediated repression. Exon skipping was restored by 
expression of PTBP1-MS2 fusion proteins, including a deletion mutant 
retaining just RRM2 and the following interdomain linker (referred to as 
RRM2L). Further deletion of either the linker or RRM2 abolished activity. The 
linker contains the site of a 26 amino acid insert that differentiates the major 
expressed PTBP1 isoforms from each other (Fig. 1, 2A), and the longer 
isoform of RRM2L showed stronger activity in the MS2 assay [27]. Recently, 
the enhanced activity of the longer isoform was shown by the Blencowe lab to 
apply to numerous alternative splicing events (ASEs), and was particularly 
relevant for a set of ASEs that change early during neuronal differentiation, in 
response to the shift from the long to the short linker isoform of PTBP1 [28]. 
The generation of long and short PTBP1 isoforms with differential activity was 
shown to be an evolutionary innovation acquired by mammals but not other 
vertebrate lineages [28]. Interestingly, PTBP2 lacks the exon responsible for 
the longer variant of the linker, while in PTBP3 this segment is constitutively 
included. Although this is not the only site of variation it is an interesting 
possibility that this region might influence differential activities between PTB 
paralogs.  
 RRM2 was first found to interact with proteins as well as RNA by 
investigation of the PTB-interacting protein Raver1 [29], overexpression of 
which promotes Tpm1 exon 3 skipping [30]. Interaction of Raver1 with PTB is 
mediated by 4-5 short heptapeptide motifs — termed PTB RRM2 Interaction 
(PRI) motifs. The Raver1 PRI motifs are sufficient for PTB interaction and 
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necessary for Raver1 activity [31]. Raver1 PRI1 (GLLGAPP) and PRI3 
(SLLGEPP) bind PTBP1 with higher affinity than PRI2 and 4, and are 
conserved in the paralog Raver2 [32]. Limited mutagenesis of PRI3 
established a consensus PRI motif of [S/G][I/L]LGx φP, where φ is a small 
hydrophobic side-chain [31, 33]. NMR analysis established that the PRI3 
peptide interacted with RRM2 on the opposite face from the RNA binding 
surface, and that RRM2 could form a ternary complex with RNA and PRI 
peptide [31]. Crystallographic analysis of PRIs covalently linked by a flexible 
tether to RRM2 provided high-resolution structures of RRM2 bound to Raver1 
PRI3 (1.4 Å) and PRI4 (1.55 Å) [33]. The PRI peptide interacts with the alpha 
helical face of RRM2 perpendicular to the two helices, similar to the mode of 
interaction of U2AF homology motif (UHM) domains of U2AF65 and U2AF35 
with their UHM ligand motif (ULM) peptides [34, 35]. While ULMs have a 
characteristic tryptophan residue that docks into a pocket on the UHM dorsal 
surface, the PRI di-leucine motif docks into a shallower hydrophobic pocket 
on RRM2. PTBP1 Tyrosine 247 is a particular focus of hydrophobic and 
carbon-pi interactions and the di-Proline motif of PRI3 fits in a pocket between 
Tyr247 and Tyr193 (Fig. 2A). Mutation of tyrosine 247 to glutamine (Y247Q) 
impaired interaction of RRM2 with PRI peptides but not with RNA, confirming 
the importance of this residue to protein-protein interactions. Moreover, the 
mutation reduced the activity of RRM2L-MS2 in the tethered function assay 
arguing for the functional importance of PRI-binding by PTBP1 RRM2 [33]. 
 Despite the detailed structural analysis of Raver1-PTBP1 interactions, 
a Raver1 knockout mouse showed no obvious alternative splicing defects 
[36]. Moreover, knockdown of HeLa cell Raver1 had only modest effects upon 
the transcriptome, with no observed upregulation of Raver2 which might have 
compensated for loss of Raver1 (M. Hallegger & CWJS, unpublished 
observations). Nevertheless, the specificity of the PTBP1-PRI interaction and 
the conservation of the PRI binding surface in the PTBP2 and PTBP3 
paralogs  [33] (Fig. 3C), suggested that it mediates functional interactions. We 
therefore carried out pull-down experiments from HeLa cell nuclear extracts 
using wild type (WT) and Y247Q PTBP1 RRM2 [15]. Numerous proteins in 
the nuclear extract interacted with WT but not Y247Q RRM2, the two most 
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prominent of which were Raver1, as expected, and the nuclear matrix protein 
Matrin3. Several of the interacting proteins contained sequences that match 
the established PRI consensus (Fig. 2B), and that interacted with GST-PTB 
(Fig 2C). These proteins were associated with various nuclear functions, with 
some of which PTBP1 has previously been associated. For example, PTBP1 
regulates some 3´ end processing sites [37], and two 3’ end processing 
factors, WDR33 and CSTF2, with PRIs were identified in the pull-down (Fig 
2B). This suggests that PTB could activate selected polyA sites by binding 
nearby and helping to recruit WDR33 or CSTF2. Two other interesting PRI 
motif containing binding partners were the paralogs CCAR2/DBC1 and 
CCAR1 [38], both of which, among numerous other functions, have been 
associated with splicing. CCAR2 can help RNA polymerase II overcome 
difficult to transcribe regions and thereby alter exon inclusion co-
transcriptionally [39], while CCAR1 is a spliceosomal A-complex component 
[23]. They share several domains, and in the N-terminus both have at least 
one PRI motif (Fig 2B,C). Both proteins represent potentially interesting 
targets for PTBP1’s roles in splicing regulation.  
 
Matrin 3 – a novel regulator of alternative splicing 
The most abundant RRM2 interacting protein we identified was Matrin3 [15], 
which was originally identified as a prominent nuclear matrix protein (reviewed 
in [40]). It has a pair of DNA binding binding C2H2 Zn finger domains and two 
RNA binding RRM domains. Matrin3 has been suggested to play roles in a 
number of nuclear processes, but clear evidence in support of a direct role 
has been lacking in most cases. Given its association with a well-known 
splicing regulator we tested whether Matrin3 plays a role in regulating AS. By 
transcriptome analysis of Matrin3 knockdown in HeLa cells we found that 
Matrin3 acted widely as a splicing regulator, principally as a repressor of 
cassette exons [15]. When compared with previous data on PTB target exons 
[1], only 18% of Matrin3 regulated events were also targets of PTB, showing 
that for the majority of splicing events Matrin3 acts independently of PTB. In 
retrospect, this is perhaps not surprising; RBM20, which is one of Matrin3’s 
closest relatives [40], has been found to regulate AS in cardiomyocytes [41, 
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42] even though it has no reported interactions with PTBP1 and does not 
possess a PRI motif. This supports the concept that Matrin3 and related 
proteins can operate as independent RNA-binding splicing regulators. 
Integration of Matrin3 iCLIP data with the transcriptome data revealed that 
Matrin3 is a direct regulator of exons that it represses and that it binds within 
the exons and within extended regions (up to 500 nt) of the flanking introns, 
which are larger on average than the introns flanking other cassette exons. 
Optimal binding motifs for Matrin3’s RRM domains were enriched in the 
adjacent 250 nt of the introns to each side, but not within the cassette exons 
themselves. Finally, we found that Matrin3’s RRM domains and PRI were 
necessary for regulation of two model ASEs, but the DNA binding Zn fingers 
were dispensable. Taken together with the known self-association of Matrin3 
[43], the data suggest that Matrin3 acts by binding at high affinity sites 
followed by spreading to create a wide silenced region of RNA. Such models 
have been suggested previously for other splicing regulators (e.g. [44]), but 
Matrin3 is the first for which a splicing map derived from transcriptome-wide 
data suggests that this is a general mechanism. We are currently testing this 
model for Matrin3 action, as well as addressing why Matrin3 needs its PRI 
motif to regulate ASEs that are independent of PTBP proteins.  
A wider network of PRI-RRM interactions? 
There are suggestions that both sides of the PTB-PRI interaction may be 
more diverse than we currently know. On the RRM side stands the intriguing 
observation that Matrin3 requires its PRI motif, even for ASEs that are not co-
regulated by PTBP1, suggesting that this PRI can interact with proteins other 
than PTBP1. On the PRI side, we know that many proteins interact with 
PTBP1 RRM2 in a Y247Q sensitive way, despite lacking a recognisable PRI 
motif. One explanation is that some of these proteins could be piggy-backing 
on direct interactors that possess a PRI motif. A second possibility is that 
some direct interactors may contain PRI motifs that do not conform to the 
consensus established by limited mutagenesis [31, 33]. 
As a first step to addressing the potentially wider spectrum of RRM-PRI 
interactions we have used a structural bioinformatics approach. The mCSM 
web-server was designed to predict the effects of missense variants upon 
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protein domain stability, but has been extended to predict effects upon 
protein-protein (mCSM-PPI), protein-nucleic acid (mCSM-NA) and protein-
ligand (mCSM-Lig) interactions [45-47]. Using the structure of RRM2 bound to 
Raver1 PRI3 [31, 33], computational saturation mutagenesis was carried out 
to predict the effects upon RRM-PRI interaction of mutations to all other 
amino acids of each residue of the PRI motif and of the PRI interaction 
surface of RRM2. From the PRI side the mCSM-PPI predictions agreed with 
alanine scanning mutagenesis data from V498-P505 (Fig 3A) [31, 33]. Of 
particular interest, a number of previously untested sequence variants are 
predicted to increase the affinity of interaction, including aromatic side-chains 
in place of the di-leucine motif and also, more surprisingly, replacement of 
Proline 505 by aspartate or glutamate. Encouragingly, some of the Y247Q 
sensitive RRM2 interacting proteins contain potential PRI motif variants 
suggested by mCSM-PPI predictions. For example SUGP2, which was 
identified by GST-PTBP1 pull-downs from HeLa nuclear extracts [15] (Fig. 
2B), in co-immunoprecipitation from HEK 293T cells (MC & CWJS 
unpublished observations), and in a global interactome survey [24], has the 
motif SLLGKGE. We are currently testing the functionality of some of these 
predicted novel PRI motif variants.  
 mCSM-PPI was also used to explore the effects of sequence variants 
in the 12 positions that constitute the peptide binding surface of PTBP1 
RRM2. The critical role of Y247 was highlighted by the predicted deleterious 
effects of all mutations at this site (Fig 3B). Likewise, all mutations at Y193, 
V199, L241, N245, I246, N248 and L253 are predicted to impair PRI 
interaction. The PRI interacting residues are fully conserved between PTBP1, 
2 and 3, and only one position (N248D) varies in the rodent restricted smPTB, 
[48]. Moreover, comparison with the RRM2 domains of hnRNPL and 
hnRNPLL, which are the next closest relatives (44 and 41% identity) and 
share characteristic structural features [49], shows that 6-7 of the positions 
are conserved, all of these corresponding to positions at which all mutations in 
PTBP1 would impair PTB-PRI interaction (Fig 3B,C). Moreover, in 4 of the 6 
positions in hnRNPL/LL that vary from PTBP1, some mutations in PTBP1 are 
predicted to improve interaction. This suggests that the hnRNPL family 
proteins might also interact with co-regulators via their RRM2 domains, and 
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that these interacting proteins will also possess short linear peptides similar to 
the PRI motifs. Given the similarity, but non-identity, of their predicted peptide-
binding surfaces, it might be expected that some interacting proteins might be 
shared between PTB and hnRNPL proteins, while others might be unique to 
each protein family. Indeed, Matrin3 is known to interact with hnRNPL [43, 50] 
although there is no evidence that this is mediated by the Matrin3 PRI. Thus, 
rather than being an interaction module unique to PTB, the PTB-PRI interface 
might be a prototype for a more extended network of protein-protein 
interactions, perhaps similar to the set of interactions between the UHM 
domains of U2AF1, U2AF2, SPF45, PUF60, KIS and HCC1 and the ULM 
ligands of SF3B1, SF1 and U2AF2 [34]. If this is the case, it raises the 
question of how the appropriate RRM-PRI interactions are selected. A clue to 
the answer is provided by the low affinity (KD ~ 100 µM) of the interaction 
between PTBP1 RRM2 and the strong PRI3 from Raver1 [31]. This suggests 
that PRI-RRM interactions might function in the context of multivalent 
interactions in multi-component regulatory RNP assemblies. We are 
addressing these possibilities in our continuing investigation of the extent and 
roles of PRI-RRM interactions.  
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Figure legends 
Figure 1. A post-transcriptional network controlling expression of 
PTBP1, 2 and 3. Full length PTBP1 protein causes skipping of its own exon 
11 (top), the equivalent exon 10 in PTBP2 (lower left) and exon 2 of PTBP3 
(lower right). Skipping of PTBP1 exon 11 and PTBP2 exon 10 is frame-
shifting, leading to insertion of a premature termination codon (stop sign) and 
Nonsense Mediated Decay. In most cell types, the cellular levels of PTBP1 
cause a small amount of PTBP1 exon 11 skipping, limiting its overexpression 
[51], but almost complete skipping of PTBP2 exon 10, effectively switching 
PTBP2 expression off. PTBP1 also causes almost complete skipping of 
PTBP3 exon 2, which leads to production of two N-terminally truncated 
isoforms both lacking the N-terminal nuclear localization signal (red bar), and 
one of which lacks most of the first RRM domain. The relative amounts of the 
competing pathways in the presence of normal levels of PTBP1 are indicated 
by the thickness of the diagonal dashed lines. This network can be modulated 
by post-transcriptional down-regulation of PTBP1 [7, 11]. 
 
Figure 2. PTBP1 domain organization and protein interactions 
A) Schematic of PTBP1 domain organization, with four RNA Recognition Motif 
(RRM) domains, and N-terminal region containing a bipartite nuclearl 
localization signal and nuclear export signal (red), and a 26 amino acid 
alternatively spliced segment (grey) between RRMs 2 and 3. Lower: 
interaction of the dorsal surface of RRM2 with the peptide SLLGAPP [33]. 
Peptide: cyan, RRM2 green, Y247 grey.  
B) Proteins with potential PRI motifs identified to interact with PTBP1 RRM2 in 
a Y247Q sensitive manner [15]. Mismatches from the current PRI consensus 
are indicated by lower case. The Raver1 PRI motif in parentheses is 
necessary for full Raver1 activity (C. Gooding, unpublished observations), but 
has not been shown to interact with PTBP1. SUGP2 is included on the basis 
of mCSM-PPI predictions (Fig 3A). 
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C) GST-PTBP1 pull-down of [35S] methionine labelled in vitro translated PRI 
peptides. Upper row, input; middle row, GST-PTBP1 pulldown; lower row, 
GST pulldown.  
 
Figure 3. Computational mutagenesis of PRI-RRM interface 
A) and B) Heatmaps of mCSM-PPI predictions of effects on protein-peptide 
affinity of mutations in VSLLGAPP peptide (A) and PTBP1 RRM2 (B) 
mutations. Red, destabilizing; blue, stabilizing. 
C) Alignment of critical PRI-interacting residues of PTBP1 with equivalent 
residues in PTBP2, PTBP3, hnRNPL and hnRNPLL. Cells are colour-coded to 
indicate whether amino acid changes in hnRNPL and LL were predicted to be 
stabilizing or destabilizing in the PTBP1-PRI interaction in panel B. Numbers 
in top row are amino acids positions in human PTBP1. 
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